Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Tumors

In brief

To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.

Key facts

Study ID

NCT00201812

Run by

Ohio State University Comprehensive Cancer Center

People needed

27

Starts

2000-11-01

Expected to finish

2005-05-01

Last updated by the study team

2017-12-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.
• Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:
• Non-Small Cell Lung
• Breast
• Head and Neck
• Esophageal
• Stomach
• Ovarian carcinomas
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
• Life expectancy of at least 12 weeks.
• Must have adequate organ function
• Peripheral Neuropathy must be less than Grade 2

Where it is running

• Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.